东方生物成立20周年：从安吉走向全球，铸就体外诊断领域创新标杆

Core Insights - The core message of the news is the celebration of the 20th anniversary of Dongfang Biological, highlighting its journey from a startup in Anji, Zhejiang to a significant player in the global in vitro diagnostics field, emphasizing technological innovation, market expansion, and future strategies [1] Group 1: Company History and Development - Dongfang Biological was founded in 2005 in Anji, benefiting from a favorable natural and business environment, which laid the groundwork for its growth [2] - The company established its first overseas subsidiary in the U.S. in 2007, marking its initial foray into international markets [2] - By 2025, Dongfang Biological has achieved 1,688 international certifications across dozens of countries, establishing a robust global presence [2] Group 2: Technological Advancements - The company has focused on technological innovation, evolving from a single product supplier to a comprehensive solution provider with six core technology platforms [3] - Dongfang Biological has developed a product matrix for respiratory testing that includes 126 professional and home testing scenarios, gaining FDA De Novo certification for home testing kits [4] - The company has achieved a total of 2,399 medical device registrations by the end of 2024, showcasing its technological capabilities [3] Group 3: Global Expansion Strategy - Dongfang Biological has established over 50 subsidiaries globally and built a team of nearly 3,000 employees, with a focus on local production and service [5] - The company's global strategy has evolved from "China to Global" to "Global to Global," emphasizing the integration of global resources and local production capabilities [6] - During the COVID-19 pandemic, the company became a major supplier of COVID-19 testing products, demonstrating resilience in its global operations [6] Group 4: Domestic Market Focus and New Ventures - The company is focusing on expanding its domestic market from 2024 to 2025, recognizing the growth potential in China's in vitro diagnostics market [7] - Dongfang Biological is entering the animal health sector, having obtained GMP certificates and production licenses for veterinary drugs, and is developing a range of products for pet diagnostics [8] - The company aims to leverage its multi-technology platforms to provide comprehensive solutions in both human and animal health sectors [8]